

Faculty of Medicine and Health Sciences: Research Development and Support 23 April 2019 (#13)

[Click on blue hyperlink for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit <u>www.grants.nih.gov</u> or <u>www.sun.ac.za/RDSfunding</u> (current & archive).

Confirm your intent to apply ASAP, but not later than **60 days** before the submission date. Tygerberg Campus: <u>cdevries@sun.ac.za</u> • Stellenbosch Campus <u>lizelk@sun.ac.za</u>

Important Notices & News

- New FAQs for NIH-MRC U.S.-South Africa Collaborative Research
- <u>Tips for Writing a Strong Multiple PI Leadership Plan</u> Reviewers will judge the Leadership Plan of an application with multiple principal investigators (PIs) for its scientific merit and whether it promotes enough coordination and communication among PIs.
- The multiple PI approach for new investigators. If you are a new investigator and want to submit a multiple PI grant application, consider the benefits versus the potential downsides. For example, if a new investigator has an established investigator as the second PI, the application *is not eligible for the special new investigator payline.* For more information, visit NIAID's Multiple Principal Investigators page.
- <u>Wanted: Innovative Informatics Approaches to Immunology</u> NIAID plans to fund contributors proposing new analytical approaches to immunology data within the Immunology Database and Analysis Portal.
- A recent Notice of Special Interest (NOSI) calls for research on the biological, clinical, behavioral, and social processes that affect the health and development of sexual and gender minority populations. <u>Find an NIAID</u> <u>area of interest in an NIH NOSI</u>

• Understanding NIH Resubmission Rules

- Only a single <u>resubmission (A1)</u> of a competing <u>new</u>, <u>revision</u> or <u>renewal</u> application (<u>A0</u>) will be accepted.
- Following an unsuccessful *resubmission* (A1) application, applicants may submit the same idea as a *new* (A0) application for the next appropriate *new* application due date (see <u>NOT-OD-18-197</u> for exceptions).
- Resubmissions (A1s) must be submitted within 37 months of the last competing *new*, *revision*, or *renewal* (A0) application.
- Visit the <u>Resubmission Applications</u> page

Steps following an unfunded *resubmission*: If your *resubmission* of a *new* application is not awarded, you can **try again as a** *new* **application**. Remember, not to mention your previous submission or reviewer feedback anywhere in your application - not even the cover letter. By all means, make any changes necessary to address reviewer feedback and strengthen your application, just don't explicitly point out what you changed or why. When you submit your *new* application, it will be treated like it has never been seen before.

1. HEAL Initiative: Early Phase Pain Investigation Clinical Network - Specialized Clinical Centers (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due dateHyperlink: (RFA-NS-19-036)Type: U24Application Due Date:June 3, 2019. Apply by 5:00 PM local time of applicant organization.Tupe: U24

Funding Opportunity Announcement: The purpose of this funding opportunity announcement (FOA) is to invite applications for the Specialized Clinical Centers ("hubs") of the Early Phase Pain Investigation Clinical Network (EPPIC-Net). EPPIC-Net will serve as the cornerstone of the NIH's Helping to End Addiction Long-term (HEAL) Initiative. EPPIC-Net will provide a robust and readily accessible infrastructure for carrying out in-depth phenotyping and biomarker studies in patients with specific pain conditions, and the rapid design and performance of high-quality Phase 2 clinical trials to test promising novel therapeutics for pain from partners in academia or industry. Studies will bring intense focus to patients with well-defined pain conditions and high unmet therapeutic needs. EPPIC-Net will consist of one Clinical Coordinating Center (CCC), one Data Coordinating Center (DCC) and approximately 10 specialized clinical centers ("hubs"). The purpose of this funding opportunity announcement (FOA) is to invite applications for the hubs within EPPIC-Net. A hub will typically be a regional medical center that will actively enroll subjects into clinical trials and studies performed in EPPIC-Net. Each hub should have ready access to patient populations with specific pain conditions and have expertise in characterization of that pain condition. A hub will additionally provide scientific leadership and administrative oversight to its multiple (2-10) satellite sites ("spokes"). This FOA solicits applications EPPIC-Net Specialized Clinical Centers. Separate FOAs have been issued to solicit applications for the Clinical Coordinating Center (RFA-NS-19-024). Clinical trials conducted through EPPIC-Net may come from a variety of sources including the HEAL Partnership, as described above, or from separate NIH funding announcements.

Budget: NINDS intends to commit up to approximately \$2,800,000 in FY 2019 to fund 10 total awards. Future year amounts will depend on annual appropriations, but NIH expects to maintain the hubs at the same funding level through 2023. Application budgets need to reflect the actual needs of the proposed project and are limited to \$150,000 in direct costs for each year of the project period. As a cooperative agreement, NIH funds are contingent upon success of meeting milestones and the budget may be renegotiated to reflect the needs of the network and NIH priorities. Award period 5 years.

Brief definitions of some NIH grant mechanisms: comprehensive list of extramural grant and cooperative agreement activity codes

Research Development and Support Division (RDSD), Faculty of Medicine and Health Sciences, Stellenbosch University 5th Floor, Teaching Block, Tygerberg Campus. Enquiries: *Christa* e: <u>cdevries@sun.ac.za</u> | t: +27 21 938 9838 Afdeling Navorsingsontwikkeling/Division for Research Development (DRD) Stellenbosch University 2038 Wilcocks Building, Ryneveld Street Enquiries: Lizél e: lizelk@sun.ac.za | t: +27 21 808 2105